ASLAN PHARMACEUTICALS AND NATIONAL CANCER CENTRE SINGAPORE COLLABORATE

Hi Gavin (again)

I’ve been following ASLAN and spoken with one of the docs running the study in Singapore.

It’s an interesting drug since Asian development and most study – so you might not get many folks talking about it here since Asian (located) patients.

“87% Shrinkage” CCA PR Article: http://www.aslanpharma.com/download/Press%20Release%20-%20ASLAN%20ACT%20Genomics%20Collaboration.pdf

Although it’s a HER+ targeted therapy, they have opened some of the studies are open to non-HER (non-molecularly selected).

Is this normal procedure? Or do you think they have hypothesis that there is efficacy outside of Target?

https://clinicaltrials.gov/ct2/results?term=ASLAN001&Search=Search